OBJECTIVE
A
t leas
t 20 type 2 diabetes loci have now been identified, and several of these are associated with altered β-cell function. In this study, we have investigated the combined effects of eigh
t known β-cell loci on insulin secretion stimulated by three differen
t secretagogues during hyperglycemic clamps.
RESEARCH DESIGN AND METHODS
A total of 447 subjects originating from four independen
t studies in the Netherlands and Germany (256 with normal glucose tolerance [NGT]/191 with impaired glucose tolerance [IGT]) underwen
t a hyperglycemic clamp. A subse
t had an extended clamp with additional glucagon-like peptide (GLP)-1 and arginine (
n = 224). We nex
t genotyped single nucleotide polymorphisms in
TCF7L2,
KCNJ11,
CDKAL1,
IGF2BP2,
HHEX/IDE,
CDKN2A/B,
SLC30A8, and
MTNR1B and calculated a risk allele score by risk allele counting.
RESULTS
The risk allele score was associated with lower first-phase glucose-stimulated insulin secretion (GSIS) (
P = 7.1 × 10
−6). The effec
t size was equal in subjects with NGT and IGT. We also noted an inverse correlation with the disposition index (
P = 1.6 × 10
−3). When we stratified the study population according to the number of risk alleles into three groups, those with a medium- or high-risk allele score had 9 and 23% lower first-phase GSIS. Second-phase GSIS, insulin sensitivity index and GLP-1, or arginine-stimulated insulin release were no
t significantly different.
CONCLUSIONS
A combined risk allele score for eigh
t known β-cell genes is associated with the rapid first-phase GSIS and the disposition index. The slower second-phase GSIS, GLP-1, and arginine-stimulated insulin secretion are no
t associated, suggesting tha
t especially processes involved in rapid granule recruitmen
t and exocytosis are affected in the majority of risk loci.Type 2 diabetes is a polygenic disease in which the contribution of a number of detrimental gene variants in combination with environmental factors is though
t to be necessary for the developmen
t of disease. In the pas
t 2 years, results of several genome-wide association studies (GWASs) have been published (
1–
5), leading to a rapidly increasing number of detrimental type 2 diabetes susceptibility loci. More recently, i
t has indeed been shown tha
t combining information from these diabetes loci into a risk allele score for all loci enhances diabetes risk (
6–
9). However, the predictive power of this combined risk allele score is ye
t insufficien
t to substitute or largely improve predictive power of known clinical risk factors (
8,
9). A
t present, little is known abou
t how these gene variants in combination affec
t insulin secretion or insulin resistance. Based on recen
t data, mainly obtained from oral glucose tolerance tests (OGTTs), i
t was shown tha
t a combined risk allele score from gene variants associated with type 2 diabetes is associated with insulin secretion and no
t with insulin sensitivity (
10–
13). However, the OGTT is unable to distinguish between first- and second-phase insulin secretion. Furthermore, other secretagogues, like glucagon-like peptide (GLP)-1 and arginine, were no
t included in these studies.I
t is though
t tha
t the rapid recruitmen
t and release of insulin granules from the readily releasable pool (RRP) is responsible for the firs
t phase of insulin secretion, whereas the slower prolonged second phase involves recruitmen
t to the membrane of more distan
t granules and de novo insulin synthesis. Although the exac
t pathways regulating both phases of glucose-stimulated insulin secretion (GSIS) are no
t completely resolved, i
t seems logical tha
t they are a
t leas
t in par
t different. This is further corroborated by our recen
t observation tha
t the heritability for both phases of GSIS in twins is derived from partly nonoverlapping sets of genes (
13a).Also, other nonglucose, stimuli-like incretins and amino acids can evoke an insulin response. Detailed phenotypic investigations of the response to these differen
t stimuli may help to elucidate which processes are primarily affected by these loci. Previously, we have already shown tha
t type 2 diabetes genes/loci can have differen
t effects on first- and second-phase GSIS, as measured using hyperglycemic clamps. Also, based on the method of stimulation (i.e., oral versus intravenous), the outcome may differ substantially (
14–
17), which provides further clues abou
t the mechanism by which they affec
t insulin secretion.In this study, we genotyped gene variants in
TCF7L2,
KCNJ11,
HHEX/IDE,
CDKAL1,
IGF2BP2,
SLC30A8,
CDKN2A/CDKN2B, and
MTNR1B in 447 hyperglycemic clamped subjects (256 with normal glucose tolerance [NGT] and 191 with impaired glucose tolerance [IGT]) from four independen
t studies in the Netherlands and Germany. These eigh
t loci were chosen based on the fac
t tha
t they were reproducibly associated with β-cell function in various studies (rev. in
18,
19). A combined risk allele score of all eigh
t gene variants was calculated for each individual and tested agains
t the various detailed measurements of β-cell function using the hyperglycemic clamp, generally considered to be the gold standard for quantification of first- and second-phase GSIS (
20). Furthermore, we also assessed the combined effec
t of these eigh
t genes on two other stimuli, GLP-1 and arginine-stimulated insulin secretion during hyperglycemia, in a subse
t of the study sample (
n = 224). The latter tes
t provides an estimation of the maximal insulin secretion capacity of a subjec
t and may, according to animal studies, serve as a proxy for β-cell mass (
21).
相似文献